Dapagliflozin as an add-on to Insulin Therapy in Type 1 Diabetes

• Research type

  Research Study

• Full title

  A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus Pharmacogenetics Blood Sample Amendment Number 01- Site Specific, dated 10-Sep-2014

• IRAS ID

  166460

• Contact name

  Ken Darzy

• Contact email

  ken.darzy@nhs.net

• Sponsor organisation

  AstraZeneca AB

• Eudract number

  2013-004674-97

• Duration of Study in the UK

  3 years, 0 months, 15 days

• Research summary

  to be re-written

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  14/SC/1361

• Date of REC Opinion

  26 Nov 2014

• REC opinion

  Further Information Favourable Opinion